Update shared on 30 Nov 2025
Fair value Increased 5.47%The analyst price target for Roivant Sciences has increased from approximately $23.27 to $24.55. Analysts cite stronger revenue growth forecasts and recent positive clinical trial updates as factors driving an improved company outlook.
Analyst Commentary
Recent analyst reports offer a nuanced outlook on Roivant Sciences, reflecting both optimism regarding the company’s future prospects and some persistent areas of caution. Below are the key viewpoints shaping sentiment toward the stock:
Bullish Takeaways- Several bullish analysts have raised their price targets, citing strong clinical trial results and robust revenue growth forecasts.
- Positive Phase 3 data, particularly for brepocitinib in dermatomyositis and batoclimab in thyroid eye disease, have strengthened confidence in Roivant's late-stage pipeline and future commercial launches.
- Upcoming data releases and planned investor events are being viewed as key catalysts that could drive share performance into 2026 and beyond.
- Progress in ongoing litigation, especially relating to lipid nanoparticle technology, has improved sentiment around execution risk and broadened valuation potential.
- Some bearish analysts continue to point to the delay in topline data for certain Phase 3 programs, which have been postponed for competitive reasons, as creating execution timing risk.
- Ongoing intellectual property litigation, particularly the potential impact of court rulings and settlements, remains a source of uncertainty for Roivant's future financial profile.
- While commercial prospects look stronger, certain coverage initiations and target hikes come with Neutral ratings, which highlights a cautious stance on valuation until more data is available.
What's in the News
- Roivant and Priovant Therapeutics announced positive results from the Phase 3 VALOR study evaluating brepocitinib in dermatomyositis. The 30 mg dose achieved a significantly higher mean Total Improvement Score compared to placebo, and the safety profile was consistent with previous clinical trials. NDA filing is planned for the first half of 2026. (Key Developments)
- Roivant Sciences hosted an Analyst/Investor Day and provided updates on its late-stage pipeline and corporate strategy. (Key Developments)
- The company finalized a share buyback and completed the repurchase of 270,000 shares for $3.15 million under the August 2025 buyback program, representing 0.04% of shares. (Key Developments)
Valuation Changes
- Consensus Analyst Price Target has risen from $23.27 to $24.55, reflecting a modest improvement in analyst confidence.
- Discount Rate edged higher from 7.36% to 7.44%, indicating a slightly increased risk perception or cost of capital.
- Revenue Growth forecasts strengthened, increasing from 316.4% to 326.1%, suggesting analysts expect higher future sales expansion.
- Net Profit Margin has fallen significantly from 15.47% to 4.29%, highlighting expectations of reduced near-term profitability.
- Future P/E ratio surged from 76.9x to 290.4x, indicating a substantial rise in expected valuation relative to forecasted earnings.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.